文献速递MDS 与骨髓增殖性肿瘤

患者特异性合并症作为骨髓纤维化生存的预后变量

Patient-specific comorbidities as prognostic variables for survival in myelofibrosis.
PubMed 文献 · Blood Adv · 2023-01-01

研究利用生物样本库数据,回顾性分析1995至2016年在范德堡大学医学中心治疗的骨髓纤维化患者,评估患者特异性合并症对总生存的影响。发现肾功能衰竭/功能障碍、颅内出血、侵袭性真菌感染和慢性脑病与较差生存相关,将这些合并症纳入扩展DIPSS模型可提高判别能力。

要点

  • 肾功能衰竭/功能障碍与较差生存相关(HR 4.3)。
  • 颅内出血、侵袭性真菌感染和慢性脑病与较差生存相关。
  • 包含4种显著合并症的扩展DIPSS模型判别能力优于原DIPSS模型。

核心结论

  • 将合并症纳入风险评估可能增强未来基于遗传学的评分系统的预后能力。

研究设计与样本

  • 回顾性队列研究,纳入1995年至2016年在范德堡大学医学中心治疗的原发性或继发性骨髓纤维化患者,数据来自范德堡合成衍生数据库和BioVU生物样本库。

主要发现

  • 肾功能衰竭/功能障碍与较差生存相关(HR 4.3;95% CI 2.1-8.9;P=0.0001)。
  • 颅内出血与较差生存相关(HR 28.7;95% CI 7.0-116.8;P=2.83e-06)。
  • 侵袭性真菌感染与较差生存相关(HR 41.2;95% CI 7.2-235.2;P=2.90e-05)。
  • 慢性脑病与较差生存相关(HR 15.1;95% CI 3.8-59.4;P=0.0001)。
  • 包含所有4种显著合并症的扩展DIPSS模型C指数为0.81(95% CI 0.78-0.84),原DIPSS模型C指数为0.73(95% CI 0.70-0.77)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment decisions in primary myelofibrosis (PMF) are guided by numerous prognostic systems. Patient-specific comorbidities have influence on treatment-related survival and are considered in clinical contexts but have not been routinely incorporated into current prognostic models. We hypothesized that patient-specific comorbidities would inform prognosis and could be incorporated into a quantitative score. All patients with PMF or secondary myelofibrosis with available DNA and comprehensive electronic health record (EHR) data treated at Vanderbilt University Medical Center between 1995 and 2016 were identified within Vanderbilt's Synthetic Derivative and BioVU Biobank. We recapitulated established PMF risk scores (eg, Dynamic International Prognostic Scoring System [DIPSS], DIPSS plus, Genetics-Based Prognostic Scoring System, Mutation-Enhanced International Prognostic Scoring System 70+) and comorbidities through EHR chart extraction and next-generation sequencing on biobanked peripheral blood DNA. The impact of comorbidities was assessed via DIPSS-adjusted overall survival using Bonferroni correction. Comorbidities associated with inferior survival include renal failure/dysfunction (hazard ratio [HR], 4.3; 95% confidence interval [95% CI], 2.1-8.9; P = .0001), intracranial hemorrhage (HR, 28.7; 95% CI, 7.0-116.8; P = 2.83e-06), invasive fungal infection (HR, 41.2; 95% CI, 7.2-235.2; P = 2.90e-05), and chronic encephalopathy (HR, 15.1; 95% CI, 3.8-59.4; P = .0001). The extended DIPSS model including all 4 significant comorbidities showed a significantly higher discriminating power (C-index 0.81; 95% CI, 0.78-0.84) than the original DIPSS model (C-index 0.73; 95% CI, 0.70-0.77). In summary, we repurposed an institutional biobank to identify and risk-classify an uncommon hematologic malignancy by established (eg, DIPSS) and other clinical and pathologic factors (eg, comorbidities) in an unbiased fashion. The inclusion of comorbidities into risk evaluation may augment prognostic capability of future genetics-based scoring systems.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sochacki AL, Bejan CA, Zhao S, et al. Patient-specific comorbidities as prognostic variables for survival in myelofibrosis. Blood Adv. 2023. PMID: 35420683. doi:10.1182/bloodadvances.2021006318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。